AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus

Simply Wall St.

Mar 30

AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held. First Tracks Biotherapeutics is expected ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2623356312"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623356312\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623356312?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-30 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623356312","market":"sg","top_or_hot":-1,"title":"AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus","media":"Simply Wall St.","content":"<div>\n<p>AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held. First Tracks Biotherapeutics is expected ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-spin-off-reshapes-risk-profile-with-new-royalty-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 19:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-spin-off-reshapes-risk-profile-with-new-royalty-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held. First Tracks Biotherapeutics is expected ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-spin-off-reshapes-risk-profile-with-new-royalty-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-spin-off-reshapes-risk-profile-with-new-royalty-f","article_id":"2623356312","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-anab/anaptysbio/news/anaptysbio-spin-off-reshapes-risk-profile-with-new-royalty-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623356312","pubTimestamp":1774869078,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held.\nFirst Tracks Biotherapeutics is expected to list on Nasdaq and will be funded through capital from AnaptysBio and a private placement.\nThe company has added experienced industry executive Susannah Gray to its board as part of the transition.\n\nThe spin off comes as AnaptysBio, listed as NasdaqGS:ANAB, is in focus with a current share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANAB":"Anaptysbio Inc"},"translate_title":"AnaptysBio分拆通过新的特许权使用费焦点重塑风险状况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9},"content_text":"AnaptysBio has approved the spin off of First Tracks Biotherapeutics, with shareholders set to receive one First Tracks share for each AnaptysBio share held. First Tracks Biotherapeutics is expected to list on Nasdaq and will be funded through capital from AnaptysBio and a private placement. The company has added experienced industry executive Susannah Gray to its board as part of the transition.  The spin off comes as AnaptysBio, listed as NasdaqGS:ANAB, is in focus with a current share price of $57.4. The stock has seen a 27.7% gain year to date and a 208.8% return over the past year, which puts recent corporate moves like this separation under a brighter spotlight for investors following the story. For current shareholders, the one for one share distribution in First Tracks Biotherapeutics adds a new listed asset linked to AnaptysBio's antibody work. The reshaped structure, combined with the appointment of Susannah Gray, marks a new chapter that investors may want to track closely as each business pursues its own priorities and cash planning. Stay updated on the most important news stories for AnaptysBio by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AnaptysBio. NasdaqGS:ANAB 1-Year Stock Price Chart Does the team leading AnaptysBio have what it takes? See our full breakdown of the management team's track record and compensation. This spin off effectively splits AnaptysBio into a leaner, royalty focused company and a separately funded R&D platform, which changes the risk profile for existing holders. AnaptysBio plans to operate with a limited headcount, minimal operating expenses and roughly US$140 million to US$145 million in net cash and investments, while continuing to manage the Jemperli collaboration with GSK and the imsidolimab collaboration with Vanda. First Tracks Bio, in turn, launches with US$180 million in cash, including an US$80 million private placement. This gives it a dedicated pool of capital for antibody development without drawing on AnaptysBio’s balance sheet. The decision to withdraw the US$100 million at the market offering and instead authorize a share repurchase program signals a shift away from raising fresh equity at current levels and toward returning capital to shareholders. Adding former Royalty Pharma CFO Susannah Gray, who has deep royalty finance and capital markets experience, supports this pivot toward managing collaboration economics and cash returns more tightly. AdvertisementThe Risks and Rewards Investors Should Consider  ⚠️ Execution risk around running a very lean organization while still maximizing value from the Jemperli and imsidolimab collaborations. ⚠️ The business remains unprofitable and is not forecast to become profitable over the next 3 years, so cash management will be important. 🎁 First Tracks Bio is separately funded with US$180 million in cash, which may reduce funding pressure on AnaptysBio’s own balance sheet. 🎁 Analysts have flagged 2 key rewards, including that the shares trade at a large discount to one estimate of fair value and revenue is forecast to grow 20.63% per year.  What To Watch Going Forward Investors may want to monitor how efficiently AnaptysBio manages collaboration cash flows from GSK and Vanda, including any updates to milestones or royalties, as this will be central to the post spin model. The early trading performance of First Tracks Bio on Nasdaq and any clinical progress on programs such as ANB033 will also influence how the market views the decision to separate. In addition, investors can follow updates on the US$100 million share repurchase program, especially the pace and pricing of any buybacks, as this will affect both capital allocation and per share economics for remaining holders. To stay informed on how the latest news shapes the investment narrative for AnaptysBio, visit the\n                         community page for AnaptysBio to follow the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}